- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Jones Trading cuts Femasys stock target to $6, maintains Buy | 1 | Investing.com | ||
| FEMASYS Aktie jetzt für 0€ handeln | |||||
| Fr | Analyst Expectations For Femasys' Future | 2 | Benzinga.com | ||
| Fr | Femasys stock price target cut to $12 from $15 by H.C. Wainwright | 3 | Investing.com | ||
| Fr | Femasys GAAP EPS of -$0.23 | 1 | Seeking Alpha | ||
| 08.05. | FEMASYS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.05. | Femasys Inc.: Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update | 39 | GlobeNewswire (Europe) | -- Company delivers on mission to transform women's health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full... ► Artikel lesen | |
| 08.05. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 02.04. | Femasys reports FY results | 1 | Seeking Alpha | ||
| 28.03. | H.C. Wainwright maintains Femasys stock Buy rating, $15 target | 1 | Investing.com | ||
| 27.03. | FEMASYS INC - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 27.03. | FEMASYS INC - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | FEMASYS INC - 8-K, Current Report | 3 | SEC Filings | ||
| 27.03. | Femasys Inc.: Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update | 104 | GlobeNewswire (Europe) | -- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025... ► Artikel lesen | |
| 20.03. | H.C. Wainwright raises Femasys stock price target to $15 | - | Investing.com | ||
| 19.03. | Femasys Inc.: Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations | 2 | GlobeNewswire (USA) | ||
| 18.03. | Assessing Femasys: Insights From 4 Financial Analysts | 2 | Benzinga.com | ||
| 14.03. | H.C. Wainwright maintains Femasys stock Buy rating, $12 target | 1 | Investing.com | ||
| 13.03. | Femasys erhält CE-Kennzeichnung für nicht-chirurgisches Verhütungssystem | 1 | Investing.com Deutsch | ||
| 13.03. | FEMASYS INC - 8-K, Current Report | 3 | SEC Filings | ||
| 13.03. | Femasys Inc.: Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach | 114 | GlobeNewswire (Europe) | ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive... ► Artikel lesen |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 496,85 | -1,94 % | Intuitive Surgical, Inc.: Intuitive Announces CEO Transition Effective July 1, 2025 | ||
| ROKU | 61,96 | -3,71 % | It's Possible to Set Up a VPN on Roku, But You'll Need to Follow These Steps | ||
| ATOSSA THERAPEUTICS | 0,905 | +16,32 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Full Results from I-SPY 2 Endocrine-Optimization Sub-Study Evaluating Low-Dose (Z)-Endoxifen | Feasibility endpoint achieved; rapid Ki-67 suppression and substantial MRI-confirmed tumor shrinkage observed with favorable safety profile
SEATTLE, May 14, 2025 /PRNewswire/ -- Atossa Therapeutics... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports First Quarter 2025 Financial Results and Provides Business Update | SAN DIEGO, May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter... ► Artikel lesen | |
| CENTENE | 51,48 | -3,29 % | Leichter Wertverlust bei der Centene-Aktie (53,8434 €) | Die Centene-Aktie notiert heute ein wenig leichter. Zuletzt zahlten Investoren für die Aktie 59,96 US-Dollar. Ein Wertverlust in Höhe von 2,91 US-Dollar müssen derzeit die Aktionäre von Centene hinnehmen.... ► Artikel lesen | |
| VERU | 0,446 | -1,28 % | JTC Team, LLC: JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s Enobosarm Taking GLP-1 Weight Loss to Next Level | Moderated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder of Veru Watch the "KOL Connect" segment here FRENCHTOWN... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 7,050 | -100,00 % | Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update | Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment... ► Artikel lesen | |
| QUIDELORTHO | 29,800 | -1,32 % | SA analyst downgrades: QDEL, AMCX, PLYM, DAY | ||
| NANO-X IMAGING | 5,435 | -2,95 % | Nano-X Imaging LTD.: Nanox to Report First Quarter 2025 Financial Results on May 22, 2025 | ||
| FULGENT GENETICS | 17,900 | +1,70 % | Fulgent genetics targets $310M core revenue in 2025 with strong growth in diagnostics and pathology | ||
| LANTHEUS | 69,60 | -1,39 % | Truist cuts Lantheus stock price target to $117, maintains Buy | ||
| PERSPECTIVE THERAPEUTICS | 1,920 | -1,03 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results | First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinical... ► Artikel lesen | |
| AMN HEALTHCARE SERVICES | 19,500 | 0,00 % | AMN Healthcare Services Inc: AMN Healthcare Announces First Quarter 2025 Results | Quarterly revenue of $690 million; GAAP loss of ($0.03)/share and adjusted EPS of $0.45 DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator... ► Artikel lesen | |
| OMNICELL | 25,800 | 0,00 % | Omnicell's New Perioperative Clinic Setting Products May Boost Stock | ||
| ALPHATEC | 11,185 | +0,13 % | Alphatec Holdings, Inc. Announces Select Preliminary Financial Results for 2024 and Provides 2025 Outlook | CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today preliminary... ► Artikel lesen |
Das Unternehmen FEMASYS INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 1,050 Euro und damit -0,94 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FEMASYS INC finden Sie auf Wallstreet Online.